Practice Contact Information
Atlantic Health System/Morristown Medical Center
100 Madison Avenue, Second Floor
Web Site: https://findadoctor.atlantichealth.org/provider/Missak+Haigentz%2C+Jr./641677?unified=Haigentz&sort=networks%2Crelevance
Areas of Interest in Head and Neck Surgery
Dr. Haigentz, medical director of Hematology/Oncology for Atlantic Health System, is recognized nationally and internationally as an expert in cancers of the head and neck, including thyroid cancers, and in lung cancers. As past director of the clinical trials office of the National Cancer Institute-designated Albert Einstein Cancer Center, Dr. Haigentz has particular expertise in the design and conduct of innovative clinical trials to improve the lives of cancer patients, and he has led several multicenter and national clinical trials. His research has received funding from the National Institutes of Health and the Conquer Cancer Foundation of the American Society of Clinical Oncology. He is the author of numerous peer-reviewed manuscripts, review articles and book chapters, and he has served on the editorial board of the Journal of Clinical Oncology. He has held several leadership roles, including service as president of the New York Head and Neck Society (2014-2015).
Throughout his career, Dr. Haigentz has taken pride in providing compassionate and personalized cancer care. He was recruited in 2017 from the Albert Einstein College of Medicine, where he was Professor of Clinical Medicine and director of the clinical trials office of the NCI-designated Albert Einstein Cancer Center, to help create and lead a novel, academically-oriented and subspecialty-based clinical and research practice in the community setting. In 2019, Dr. Haigentz became Principal Investigator for the Atlantic Health Cancer Consortium, leading the first NCI Community Oncology Research Program (NCORP) site based in New Jersey. His clinical and research practice is focused on thoracic and head and neck cancers.
- EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA NCT03811015
- IOV-COM-202: A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors NCT03645928